MeiraGTx Holdings plc

MeiraGTx is a vertically integrated, clinical-stage genetic medicines company focused on developing locally delivered genetic therapies for serious inherited and common disorders. Its clinical pipeline targets conditions including radiation-induced xerostomia, Parkinson’s disease, and inherited retinal dystrophies. The company designs and produces gene therapy candidates using internal end-to-end good manufacturing practices capabilities, encompassing viral vector production, plasmid DNA manufacturing, and quality control. In addition to therapeutic candidates, the enterprise develops proprietary technologies such as an oral small molecule-controlled synthetic riboswitch gene regulation platform, specialized delivery devices for central nervous system administration, and a T-cell progenitor cell therapy platform. Its pipeline activities serve patients through clinical research and strategic development collaborations with global pharmaceutical partners.

The company conducts operations across the United Kingdom, Ireland, and the United States, alongside research activities in France. Its manufacturing and testing infrastructure includes a 29,000-square-foot viral vector facility in London, United Kingdom, and a 150,000-square-foot campus in Shannon, Ireland, which houses commercial-scale viral vector and plasmid DNA production. The provided text does not state the company's corporate headquarters location.

Summary of the business section of MeiraGTx's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 403 employees, 400 of which are full-time employees.”